S&P Futures
3,848.50+29.25(+0.77%)Dow Futures
31,971.00+195.00(+0.61%)Nasdaq Futures
12,443.75+146.50(+1.19%)
CSL Limited (CSL.AX)
Chart Events
Performance Outlook
| Previous Close | 246.00 |
| Open | 245.00 |
| Bid | 250.03 x 13700 |
| Ask | 250.16 x 21700 |
| Day's Range | 242.00 - 251.16 |
| 52 Week Range | 242.00 - 332.68 |
| Volume | 826,047 |
| Avg. Volume | 851,763 |
| Market Cap | 113.826B |
| Beta (5Y Monthly) | 0.10 |
| PE Ratio (TTM) | 42.79 |
| EPS (TTM) | 5.85 |
| Earnings Date | Feb 18, 2021 |
| Forward Dividend & Yield | 2.81 (1.14%) |
| Ex-Dividend Date | Mar 04, 2021 |
| 1y Target Est | 151.95 |
Fair Value
Related Research
- PR Newswire
Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older
Seqirus, a global leader in influenza prevention, today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication for people two years of age and older.1 FLUCELVAX QUADRIVALENT was previously FDA-approved for use in persons four years of age and older. FLUCELVAX QUADRIVALENT will be available as a 0.5ml intramuscular (IM) vaccine per dose for the 2021/22 U.S. influenza season.
- Simply Wall St.
A Look At The Fair Value Of CSL Limited (ASX:CSL)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CSL Limited ( ASX:CSL...
- Simply Wall St.
Declining Stock and Solid Fundamentals: Is The Market Wrong About CSL Limited (ASX:CSL)?
With its stock down 6.4% over the past three months, it is easy to disregard CSL (ASX:CSL). However, a closer look at...
